ABBV/ENTA will present detailed results of three more phase-3 trials—SAPHIRE-1, SAPHIRE-2, and TURQUOISE-2—in oral presentations at EASL, April 10-12, 2014:
TURQUOISE-2 should receive a lot of attention insofar as it’s the only large phase-3 trial with results for any HCV regimen in 100% cirrhotic patients.
Also at EASL is an oral presentation of a phase-2 trial called M12-999 that tested ABBV/ENTA’s 3-DAA regimen in liver-transplant recipients.
Note: Detailed results of PEARL-3 were presented at CROI in February (#msg-98175067), so PEARL-3 warrants only a poster presentation at EASL.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.